Vol. 8, Issue 6 (2019)

Author(s):
Sai Laxmi Kesana, Dodle Jaya Prakash, Borra Pooja and PC Sastry

Abstract:
Metabolism related liabilities continue to be of major concern in clinical development of a drug candidate. A complete understanding of the relationship between in vitro and in vivo metabolism is important. Metabolite profiling and drug phenotypic studies using specific CYP enzymes would selectively demonstrate the metabolic pathway and the interactions of the drug without the usage of animal models. In many cases in vitro studies, owing to their inexpensiveness and ease of carrying, serve for adequate screening mechanism that can rule out the importance of the in vivo metabolic studies and make in vivo testing reasonably less and even unnecessary in the early screening, in addition the clinical relevance of the results obtained using human microsomes is comparable and yet times give the complete understanding about the compounds behaviour very aptly.